Lee S, Zhou J, Leung KSK, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07319-x

Zhou J, Lee S, Leung KSK, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Fail. 2022;9(2):1388–99.

Google Scholar 

Siasos G, Bletsa E, Stampouloglou PK, et al. Novel antidiabetic agents: cardiovascular and safety outcomes. Curr Pharm Des. 2020;26(46):5911–32.

CAS  Article  Google Scholar 

Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10(10):CD013650.

PubMed  Google Scholar 

Cotter G, Davison BA, Edwards C, et al. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. Am Heart J. 2021;240:73–80.

CAS  Article  Google Scholar 

Lee MMY, Ghouri N, McGuire DK, Rutter MK, Sattar N. Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes. Diabetes Care. 2021;44(5):1236–41.

CAS  Article  Google Scholar 

Suzuki Y, Kaneko H, Okada A, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):67.

CAS  Article  Google Scholar 

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

CAS  Article  Google Scholar 

Pitt B, Steg G, Leiter LA, Bhatt DL. The Role of combined SGLT1/SGLT2 inhibition in reducing the incidence of stroke and myocardial infarction in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2022;36(3):561–7.

CAS  Article  Google Scholar